Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersGastroenterology Physician in Boston, MA
NPI: 1447328711Primary Practice Location
Boston Food Allergy Center LLC Bi Network
1 Nassau St, Boston, MA
Primary Employer
Boston Food Allergy Center LLC Bi Network
bostonspecialists.org
HQ Phone
Get M.D. John's Phone Numberphone_androidMobile
Get M.D. John's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMA State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 65 | 146 |
| 2 | 99204New patient office or other outpatient visit, 45-59 minutes | 57 | 57 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 30 | 46 |
| 4 | 43239Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | 13 | 13 |
Discovery of an agonistic Siglec-6 antibody that inhibits and reduces human mast cells.
Authors: Schanin, Julia, Korver, Wouter, Brock, Emily C, Leung, John, Benet, Zachary, Luu, Thuy, Chang, Katherine, Xu, Alan, De Freitas, Naomi, Luehrsen, Kenneth, Brehm, Michael A, Wong, Alan, Youngblood, Bradford A
Journal: Commun Biol
Publication Date: 2022-11-11
Eosinophilic Esophagitis Patients Are Not at Increased Risk of Severe COVID-19: A Report From a Global Registry.
Authors: Mirna Chehade
Publication Date: 2021-08-11
IgE-mediated hypersensitivity to ondansetron and safe use of palonosetron.
Authors: Autumn Guyer, Aleena Banerji
Journal: J Allergy Clin Immunol Pract
Publication Date: 2013-06-25
Lead Sponsor: Shire
Intervention / Treatment: DRUG: Placebo, DRUG: Oral Budesonide Suspension (OBS)
Lead Sponsor: Children's Hospital Medical Center, Cincinnati
Collaborators: National Institutes of Health (NIH), Regeneron Pharmaceuticals
Intervention / Treatment: DRUG: Placebo (blinded), DRUG: Dupilumab (blinded), DRUG: Dupilumab (open-label)
Lead Sponsor: Children's Hospital Medical Center, Cincinnati
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), National Center for Advancing Translational Sciences (NCATS), Office of Rare Diseases (ORD)
